vestronidase alfa: clinical use

Prescribing considerations

• Specialist supervision and administration by staff equipped to manage anaphylaxis are required.
• Avoid infusion during an acute febrile or respiratory illness.
• Periodically assess whether meaningful benefit or disease stabilisation is present; withdrawal may cause clinical deterioration.
• Treatment is unlikely to reverse established irreversible complications or affect neurological disease.
• Consider sodium and fluid exposure in patients requiring restriction.

Contraindications and cautions

• Life-threatening hypersensitivity or anaphylactic reaction to vestronidase alfa or an excipient.

Monitoring

• Monitor during infusion for hypersensitivity and provide post-infusion observation.
• Monitor for spinal or cervical cord compression and neck instability.
• Record the product name and batch number for biological traceability.
• Assess clinical response periodically.
• Safety and efficacy have not been evaluated adequately in renal or hepatic impairment or established in people older than 65 years.

Clinical pharmacology

Recombinant human beta-glucuronidase is taken into cellular lysosomes, where it supports catabolism of accumulated glycosaminoglycans. As a protein, it is degraded into peptides and amino acids.

Formulation and product differences

• Available as a sterile, colourless to slightly yellow concentrate requiring aseptic dilution with sodium chloride solution before intravenous infusion.
• Each vial is single use; the product contains sodium and must not be frozen or shaken.

Solution for infusion

Route: Intravenous

Strengths: 2 mg/mL